Adipose tissue and lipolysis signalling.
Acting directly on fat tissue to increase fat breakdown or reduce its blood supply.
This pathway groups compounds that act on adipose tissue itself rather than on appetite. Lipolysis is the enzymatic breakdown of stored triglycerides into free fatty acids and glycerol, executed by adipose triglyceride lipase and hormone-sensitive lipase inside the fat cell. It is normally triggered by catecholamines acting on beta-adrenergic receptors, which raise cyclic AMP and activate protein kinase A. Growth hormone also stimulates lipolysis, but it does so as part of a package that includes growth promotion and a rise in insulin resistance. Several compounds here derive from the observation that growth hormone's fat-mobilising activity appears to reside in the carboxy-terminal region of the molecule, separate from the domain that binds and activates the growth hormone receptor. Isolating that region was intended to produce fat breakdown without raising IGF-1 or impairing glucose handling. Mechanistic work in rodents linked the effect to beta-3 adrenergic receptor activity rather than to growth hormone receptor signalling. One member of this group is the plain fragment; another is a modified analog with an added amino-terminal residue and considerably more development history behind it. A second, entirely different approach targets the blood supply instead of the fat cell. A homing sequence binds prohibitin, a protein unusually abundant on the endothelial cells lining blood vessels within white adipose tissue, and delivers a pro-apoptotic sequence that kills those cells once internalised. The intent is to shrink fat depots by starving them of perfusion. This is a vascular-targeting strategy borrowed from oncology and is conceptually unrelated to lipolysis. A third approach targets an enzyme, nicotinamide N-methyltransferase, which is highly expressed in adipose tissue and consumes both nicotinamide and methyl groups from S-adenosylmethionine. Inhibiting it is proposed to spare nicotinamide for NAD+ regeneration and to shift adipocytes toward energy expenditure rather than storage. Clinical relevance across this group is weak. The growth hormone fragment analog was carried into human obesity trials and did not produce clinically meaningful weight loss beyond placebo, and it was not approved as a medicine. The plain fragment has essentially no human evidence of its own and borrows its reputation from that analog. The vascular-targeting compound raised kidney toxicity concerns in primate work and did not progress. The enzyme inhibitor's downstream logic is plausible but largely inferred from animal and cell studies. None of these are approved for any use.
Peptides acting through this pathway.
FAQ.
What does adipose tissue and lipolysis signalling do?
This pathway groups compounds that act on adipose tissue itself rather than on appetite. Lipolysis is the enzymatic breakdown of stored triglycerides into free fatty acids and glycerol, executed by adipose triglyceride lipase and hormone-sensitive lipase inside the fat cell. It is normally triggered by catecholamines acting on beta-adrenergic receptors, which raise cyclic AMP and activate protein kinase A. Growth hormone also stimulates lipolysis, but it does so as part of a package that includes growth promotion and a rise in insulin resistance. Several compounds here derive from the observation that growth hormone's fat-mobilising activity appears to reside in the carboxy-terminal region of the molecule, separate from the domain that binds and activates the growth hormone receptor. Isolating that region was intended to produce fat breakdown without raising IGF-1 or impairing glucose handling. Mechanistic work in rodents linked the effect to beta-3 adrenergic receptor activity rather than to growth hormone receptor signalling. One member of this group is the plain fragment; another is a modified analog with an added amino-terminal residue and considerably more development history behind it. A second, entirely different approach targets the blood supply instead of the fat cell. A homing sequence binds prohibitin, a protein unusually abundant on the endothelial cells lining blood vessels within white adipose tissue, and delivers a pro-apoptotic sequence that kills those cells once internalised. The intent is to shrink fat depots by starving them of perfusion. This is a vascular-targeting strategy borrowed from oncology and is conceptually unrelated to lipolysis. A third approach targets an enzyme, nicotinamide N-methyltransferase, which is highly expressed in adipose tissue and consumes both nicotinamide and methyl groups from S-adenosylmethionine. Inhibiting it is proposed to spare nicotinamide for NAD+ regeneration and to shift adipocytes toward energy expenditure rather than storage. Clinical relevance across this group is weak. The growth hormone fragment analog was carried into human obesity trials and did not produce clinically meaningful weight loss beyond placebo, and it was not approved as a medicine. The plain fragment has essentially no human evidence of its own and borrows its reputation from that analog. The vascular-targeting compound raised kidney toxicity concerns in primate work and did not progress. The enzyme inhibitor's downstream logic is plausible but largely inferred from animal and cell studies. None of these are approved for any use.
Which peptides act through adipose tissue and lipolysis signalling?
HGH Fragment 176-191, AOD-9604, Adipotide, 5-Amino-1MQ. They share this pathway but differ in evidence, approval, and safety.
Does this mechanism prove a peptide works?
No. Mechanistic plausibility is not proof of clinical benefit. A plausible pathway is a reason to study a compound, not evidence that it works in humans.